Abstract
Objective: To review the safety of testosterone (T) therapy with regard to the prostate, with special emphasis on the controversial association between testosterone and prostate cancer.
Methods: We reviewed the existing scientific and medical literature pertaining to the impact of T treatment on the prostate.
Results: No large-scale, long-term controlled studies of T therapy versus placebo have yet been performed to document prostate safety. However, there is a wealth of evidence from smaller clinical trials as well as population-based longitudinal studies that fails to demonstrate any signal suggesting that T therapy in hypogonadal adult men poses an increased risk of prostate cancer. New evidence indicates that exogenous T does not raise intraprostatic T or dihydrotestosterone concentrations. Indeed, there is accumulating evidence that low serum T is associated with increased risk of prostate cancer and that these cancers may have more worrisome aggressive clinical features. In addition, multiple studies have failed to show that T therapy causes worsening of voiding symptoms due to benign prostatic hyperplasia.
Conclusions: Despite the long-held belief that T therapy may pose an increased risk of prostate cancer, the available evidence strongly suggests that T therapy is safe for the prostate. Given that the population at risk for hypogonadism overlaps with the population at risk for prostate cancer, it is strongly recommended that men undergoing T therapy undergo regular monitoring for prostate cancer.
The great enemy of the truth is very often not the lie…. but the myth, persistent, persuasive and unrealistic John F. Kennedy
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Agarwal PK, Oefelein MG (2005) Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 173:533–536
Barrett-Connor E, Garland C, McPhillips JB, Khaw KT, Wingard DL (1990) A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res 50:169–173
D’Amico AV, Roehrborn CG (2007) Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol 8:21–25
Dean JD, Carnegie C, Rodzvilla J, Smith T (2004) Long-term effects of Testim 1 % testosterone gel in hypogonadal men. Rev Urol 6:S22–S29
Eaton NE, Reeves GK, Appleby PN, Key TJ (1999) Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 80:930–934
Fowler JE, Whitmore WF Jr (1981) The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 126:372–375
Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ (1996) Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88:1118–1126
Hoffman MA, DeWolf WC, Morgentaler A (2000) Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163(3):824–827
Hsing AW (2001) Hormones and prostate cancer: what’s next? Epidemiol Rev 23:42–58
Huggins C, Hodges CV (1941) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293–297
Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, Schulman C (2009) Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 56:48–56
Isom-Batz G, Bianco FJ Jr, Kattan MW, Mulhall JP, Lilja H, Eastham JA (2005) Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 173:1935–1937
Kaufman JM, Graydon RJ (2004) Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 172:920–922
Marks LS, Mazer NA, Mostaghel E et al (2006) Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 296:2351–2361
Morales A, Black AM, Emerson LE (2009) Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int 103:62–64
Morgentaler A (2006) Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 50:935–939
Morgentaler A (2007a) Testosterone replacement therapy and prostate cancer. Urol Clin N Am 34:555–563
Morgentaler A (2007b) Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship. Eur Urol 52:623–625
Morgentaler A (2012) Goodbye androgen hypothesis, hello saturation model. Eur Urol 62:765–767
Morgentaler A, Rhoden EL (2006) Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen of 4.0 ng/ml or less. Urology 68:1263–1267
Morgentaler A, Bruning CO III, DeWolf WC (1996) Incidence of occult prostate cancer among men with low total or free serum testosterone. JAMA 276:1904–1906
Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ (2005) Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 14:2257–2260
Pastuszak AW, Pearlman AM, Lai WS et al (2013a) Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol 190:639–644
Pastuszak AW, Pearlman AM, Godoy G et al (2013b) Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res 25:24–28
Rhoden EL, Morgentaler A (2003) Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 170:2348–2351
Rhoden EL, Morgentaler A (2004) Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 350:482–492
Rhoden EL, Morgentaler A (2006) Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy. Int J Impot Res 18:201–205
Sarosdy MF (2007) Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 109:536–541
Stattin P, Lumme S, Tenkanen L et al (2004) High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer 108:418–424
Wang C, Cunningham G, Dobs A et al (2004) Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone density in hypogonadal men. J Clin Endocrinol Metab 89:2085–2098
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schulman, C., Morgentaler, A. (2015). Testosterone and Prostate Safety. In: Mirone, V. (eds) Clinical Uro-Andrology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45018-5_11
Download citation
DOI: https://doi.org/10.1007/978-3-662-45018-5_11
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-45017-8
Online ISBN: 978-3-662-45018-5
eBook Packages: MedicineMedicine (R0)